Human plasma contains a multivalent, Kunitz-type proteinase inhibitor termed tissue factor pathway inhibitor (TFPI), which specifically inhibits the action of the factor VII(a) -tissue factor complex in coagulation. In the present study, we examined the distribution and anticoagulant activity of TFPI among plasma lipoprotein subspecies separated by isopycnic density gradient ultracentrifugation; this procedure permitted the simultaneous fractionation of the major ] ), whose density distribution (</=1.044 to 1.100 g/mL) overlapped that of LDL and HDL]; such association was related to Lp(a)'s particle size and phenotype. VLDL, IDL, and LDL, through LDL, (</= 1.019 to 1.039 g/mL), HDL 2 (<f= 1.063 to 1.100 g/mL), and light subtractions of HDL, (d=1.100 to 1.167 g/mL) conveyed only 1.8%, 10%, and 18.5%, respectively, of lipoprotein-associated TFPI activity. Such anticoagulant activity was dependent on the presence of TFPI protein. The dense subspecies or HDL, (d=1.133 to 1.167 g/mL) with which TFPI was preferentially associated were small, displayed a cholesteryl ester to protein ratio of -02, and were deficient in phospholipid (13.6% to 18.3%). HDL subspecies of d=1.110 to 1.167 g/mL mainly contained the higher relative molecular mass form of TFPI of 41 kD (a form that is known to be covalently associated with apolipoprotein [apo] A-II) and minor bands of the 35-and 52-kD forms. The second major localization of TFPI was within the hydrated density range of small, dense LDL particles (<f= 1.033 to 1.063 g/mL), which in comparison with light LDL (</= 1.019 to 1.033 g/mL) exhibited a markedly lower proportion of triglyceride and enrichment in cholesteryl ester. Analysb of the ratios of the percent mass of cholesteryl ester to free cholesterol in LDL subtractions showed that the increase in cholesteryl ester content was positively correlated with an increase in TFPI activity (r=.86, /" =5.0013); equally, a positive correlation between an increase in the free cholesterol to protein ratio in LDL and an increase in TFPI activity (r=.89, P S .0006) was detected. In contrast to dense apo A-I-containing lipoprotein particles, dense LDL subspecies of d= 1.039 to 1.058 g/mL mainly transported the 35-kD form of TFPI. We conclude that among the spectrum of apo B-containing lipoprotein subspecies, small, dense LDL particles provide the most favorable surface structure for efficient TFPI binding and equally, for the expression of its anticoagulant activity. 
plasma, present at concentrations of 50 to 100 ng/mL, was separated by gel filtration into three distinct fractions. 9 More than 50% of plasma TFPI was isolated in the high-molecular-weight fraction and was associated with apolipoprotein (apo) B-containing lipoprotein particles, ie, low-density lipoproteins (LDLs) and verylow-density lipoproteins (VLDLs). A second form, of intermediate molecular weight and representing 44% of plasma TFPI, was present in covalent association with apo A-II in apo A-I-containing lipoproteins, ie, highdensity lipoproteins (HDLs)," while the low-molecularweight form (6% of TFPI) was probably uncomplexed. 9 The functional and structural properties of the lipoprotein-associated forms of TFPI are, however, largely indeterminate.
It is now established that HDL appears to afford protection against coronary artery disease (CAD), 12 probably as a result of the central role of these particles in the reverse cholesterol transport system. In contrast, elevated plasma levels of LDL particles or of lipoprotein(a) (Lp[a], a structural variant of LDL) are a primary risk factor. 13 ' 14 A number of therapeutic studies have clearly demonstrated the beneficial effects of a reduction in LDL levels, and conversely of an elevation in those of HDL, on both the prevention of CAD and the regression of atherosclerotic plaques. 13 ' 16 Nevertheless, quantitative elevation of plasma LDL or subnormal concentrations of HDL do not of themselves provide an explanation for the complex mechanisms underlying CAD.
Both LDL and HDL are not structurally and metabolically homogeneous species of lipoproteins, but rather they consist of a spectrum of lipoprotein particle subpopulations of varying molecular weights, buoyant density, and composition. The physicochetnical heterogeneity of LDL particles 17 is related to differing degrees of atherosclerosis risk. 18 Indeed, dense LDL, which possesses diminished resistance to oxidative stress, may be potentially more atherogenic. 19 - 20 Equally, plasma HDLs are highly heterogeneous, reflecting the diverse pathways of formation and interconversion of these particles. Two major subclasses of HDL have been defined on the basis of density: HDL 2 and HDL,. 21 - 22 The HDL3 subclass appears to consist of particles that may correspond to primary acceptors of cellular free cholesterol. 23 In the present study, our aims were to evaluate the possible contribution of TFPI to the physicochemical heterogeneity and metabolic behavior of apo B -and apo A-I-containing lipoprotein subspecies and to compare the antithrombotic capacity of individual subspecies with their potential atherogenicity. We therefore determined the distribution of TFPI among lipoprotein subspecies, the nature of the interaction of TFPI with lipoprotein particles, and the antithrombotic activity associated with such particles. Our data demonstrate that expression of antithrombotic activity and the presence of TFPI protein are closely correlated and that such activity is primarily due to the preferential interaction of TFPI with small, dense LDL subspecies, with a particle subpopulation of the densest HDL subclass (HDLj), and with very-high-density lipoprotein (VHDL); equally, TFPI activity was associated with Lp(a).
Methods

Materials
Purified coagulation factors were of human origin except for TF, which was prepared from rabbit brain (Sigma Diagnostics). Factors Vila, X, and Xa were obtained from Diagnostica Stago (Asnieres, France). These reagents were dissolved according to the instructions of the manufacturer and further diluted in a buffer containing 0.05 mol/L tris(hydroxymethyl)aminomethane (Tris) HC1, 0.1 mol/L NaCl, 0.01 mol/L sodium citrate, and 0.02% NaN 3 ; this solution is hereafter referred to as TSC buffer. Bovine serum albumin (BSA, Sigma) was added to this solution (final concentration, 2 mg/mL) to constitute the TSC/BSA buffer. Rabbit TF was adjusted to optimal concentration with distilled water, and under such conditions the clotting time of normal plasma was 16 seconds (equal volumes of plasma, 35 mmol/L CaCl 2 » and TF). The chromogenic substrate S2222 (benzoyl-Ile-Glu-Arg-p-nitroanilide; Kabi) was dissolved in distilled water at a final concentration of 2.7 mmol/L. Low-molecular-weight standards for sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) were obtained from Pharmacia Fine Chemicals, Uppsala, Sweden. A rabbit polyclonal antibody to human TFPI was the kind gift of Dr G.J.
Broze. An 125 I-labeled antibody to rabbit immunoglobulin G (IgG) was supplied by Amersham International.
Blood Samples
Subjects were healthy normolipidemic volunteers (5 males and 3 females) who had fasted overnight. Venous blood was collected into glass bottles containing Na 3 -EDTA (1 mg/mL), from which plasma was rapidiy separated by low-speed centrifugation (lOOQg, 20 minutes) at 4°C. Immediately after collection of plasma samples, gentamicin (50 fig/mL), EDTA (0.01%), and NaN 3 (0.01%) were added. The concentrations of lipids (total cholesterol, 199±43 mg/dL plasma; total triglyceride, 61 ±15 mg/dL plasma) in each plasma sample corresponded to values typical of a normolipidemic population. 24 The mean concentration of Lp(a) was 11 ±5 mg/dL plasma.
Fractionation of Lipoproteins
Density gradient ultracentrifugation. Lipoproteins were fractionated by isopycnic density gradient ultracentrifugation using a Beckman SW41 Ti rotor at 40 000 rpm for 44 hours in a Beckman XL70 centrifuge at 15°C by a slight modification of the method described by Chapman et al. 25 Briefly, plasma density was increased to 1.21 g/mL by addition of dry, solid potassium bromide. Construction of a discontinuous density gradient at ambient temperature was initiated by pumping 2 mL of a sodium chloride-potassium bromide solution of d=1.24 g/mL into the bottom of the tube. The following solutions were then layered above: 3 mL of plasma at 1.21 g/mL; 2 mL of a sodium chloride-potassium bromide solution of d=1.063 g/mL; 2.5 mL of d= 1.019 g/mL; and 2.5 mL NaCl solution of d= 1.006 g/mL. All density solutions contained 0.01% NaN 3 , 0.01% EDTA, and 0.005% gentamicin at pH 7.4. After ultracentrifugation, gradients were collected by successive aspiration of 24 fractions, 0.4 mL each, from the meniscus downward. All fractions were dialyzed in Spectrapor mem- *A11 fractions were 0.4 mL each. tDensity limits were taken from a standard curve of density versus volume derived from control gradients containing only salt solutions (see Reference 25) and are in grams per milliliter.
Values are the means of duplicate analyses of each fraction isolated from the plasmas of eight normolipidemic subjects and are in weight percent.
§Lipoprotein mass corresponds to the sum of all lipid and protein components in each fraction.
brane tubing (relative molecular mass cutoff, 3500) at 4°C against 20 mmol/L NH4HCO3 buffer containing 0.1% EDTA at pH 7.4 before analysis. Gel filtration chromatography. Plasma samples (up to 250 mL) were ultracentrifuged in a 50 Ti rotor for 18 hours at 15°C and 45 000 rpm. The top 1-mL fraction of d< 1.006 g/mL containing triglyceride-rich lipoproteins was eliminated. The VLDL-deficient plasma (d> 1.006 g/mL; 60 mL) was then applied to a column of Ultrogel AcA 22 (height, 50 cm; diameter, 2.5 cm) at a flow rate of 0.6 mL/min. Size exclusion chromatography was carried out at 4°C; the elution buffer contained phosphate-buffered saline (PBS) and EDTA (0.1%). Fractions of 2 mL were collected and the contents of cholesterol and protein determined (see below). Fractions lacking HDL as assessed by agarose gel electrophoresis 17 were subsequently pooled and concentrated with Aquacide II (Calbiochem) to a volume of 5 mL; the samples were then applied to a Sepharose CL 4B column (Pharmacia) (height, 90 cm; diameter, 2 cm) equilibrated at 4°C with PBS. Fractions of 2 mL were collected and analyzed for cholesterol content. Cholesterol-rich fractions were identified as LDL by their -mobility on agarose gel electrophoresis.
Dissociation of Lipoprotein-Associated TFPI
LDLs prepared by gel filtration chromatography as described above were treated for 2 hours at 37°C by gentle mixing with increasing concentrations of NaCl (0.15 to 2 mol/L), dithiothreitol (1 to 50 mmol/L), e-amino-n-caproic acid (0.62 to 5 mmol/L), or heparin (0.25 to 2 U/mL). To separate any potential free TFPI from LDL, LDLs treated under the aforementioned conditions were applied to a gel filtration column (Sephadex G 100; height, 5 cm; diameter, 1 cm) and eluted with the same buffer as that used for LDL incubation. Six fractions of 4 mL were collected. In all cases, LDLs were excluded from the column and eluted in the first two fractions; 20 /xg protein of each fraction was then analyzed for TFPI protein content by denaturing SDS gel electrophoresis, followed by electrophoretic transfer to a nitrocellulose sheet and detection by autoradiography. The remaining fractions, potentially containing free TFPI, were subsequently concentrated and analyzed for TFPI activity.
Lipid and Lipoprotein Analysis
Lipids in plasma or isolated lipoprotein fractions were analyzed by enzymatic determinations using BioMerieux kits (Marcy 1 Etoile, France) for total cholesterol, free cholesterol, phospholipids, and triglycerides. 17 Cholesteryl ester mass was calculated as 1.67x (free cholesterol mass). 25 The protein content of lipoprotein fractions was determined by the procedure of Lowry et al. 26 Lipoprotein mass was calculated for each subtraction as the sum of the mass of the individual components (free cholesterol, cholesteryl ester, triglyceride, phospholipid, and protein).
Assay of TFPI Activity
TFPI activity was measured by a slight modification of the method described by Sandset et al. 1027 The assay was performed in microtitration plates in a 37°C water bath. Duplicate aliquots (25 fiL) of the test sample or standard were first distributed into wells. The amidolytic assay was performed in two stages by incubation of 100 IML of combined reagent I for 20 minutes, followed by incubation of 50 ^.L of combined reagent II for 25 minutes. Reagent I contained TF, factor Xa, factor Vila, and CaCl 2 at final concentrations of 1% (vol/vol), 5 mU/mL (0.8 nmol/L), 2.5 mU/mL (25 pmol/L), and 15 mmol/L, respectively. Reagent II was a mixture (vol/ vol) of factor X (0.4 U/mL; 60 nmol/L) and S2222 (2.7 mmol/L). The reaction was stopped by the addition of 50 /xL of 50% acetic acid. Absorbance (OD) was read at 405 nm by using a microtiter plate reader (Dynatech). Standard curves were prepared by assaying dilutions (0 to 1%) of pooled, heated, citrated plasma diluted in TSC/BSA buffer containing 2 fig/mL hexadimethrine bromide (Sigma) to prevent any influence of heparin, as was described earlier. 7 TFPI activity in 1 mL of plasma was arbitrarily defined as 100% activity (or 1 U/mL). A plot of TFPI activity (as OD403 units) as a function of progressive dilutions of a pooled plasma sample was used for calibration purposes. TFPI activity in lipoprotein subtractions was then expressed relative to the lipoprotein mass content of each subtraction. Our dilutions ranged from 0 to 25 pmol/L in our standard when using a pooled plasma at a final concentration of 2.5 nmol/L. 5 When samples were incubated with a specific polyclonal antibody to human TFPI, proteolytic cleavage of S2222 was not inhibited, demonstrating the TFPI dependence of the inhibition assay.
Enzyme-Linked Immunoassay for Lp(a)
Lp(a) was quantified by a noncompetitive enzymelinked immunosorbent assay (ELISA) with two poryclonal antibodies. An anti-human apo(a) antibody prepared in sheep 28 was used as the "capture" antibody and a peroxidase-conjugated anti-human apo B-100 antibody as the detecting antibody. 17 Both antibodies were purified by caprylic acid precipitation 29 and then concentrated by ammonium sulfate precipitation (40%). Polystyrene microtiter plates (96-well immunoplates, Costar, Cambridge, UK) were coated and left overnight at 4°C with a 100-|ig/mL dilution of antiapo(a) antibody in PBS at pH 7.4. After washing to remove unbound antibodies (washing buffer was PBS containing 0.05% Tween), the wells were blocked by incubation with 3% BSA in PBS at room temperature for 1 hour. After another wash, 100 fiL of appropriately diluted Lp(a) samples in PBS containing 0.05% Tween and 1% BSA at pH 7.4 was added to the wells. The plates were incubated for 2 hours at 37°C; they were subsequently washed and a peroxidase-labeled antibody against apo B-100 (diluted 1:800 in PBS/Tween/BSA) was added. After an additional incubation for 90 minutes at 37°C, the plates were washed and the substrate (1 mg/mL of o-phenylenediamine dihydrochloride, Sigma, in 0.05 mol/L citrate buffer at pH 5.5 containing 0.01% H 2 O 2 ) was added. The reaction was allowed to proceed in the dark for 20 minutes and was stopped with 3N HC1. Absorbance was then read at 492 nm on a Titertek multiscan microplate reader. Each plate contained eight dilutions (4 to 500 ng total Lp[a]/well) of a reference standard (Immuno-France). Periodically, purified Lp(a) was compared with the reference standard for calibration purposes. For the present ELISA, the working concentration range was 40 ng to 5 Lp(a) lipoprotein mass.
Electrophoretic Analyses
Native lipoproteins. For evaluation of lipoprotein particle size and heterogeneity, nondenaturing gradient gel electrophoresis of native lipoproteins was performed in a Pharmacia GE-2/4 LS electrophoresis apparatus loaded with gels containing a 2% to 16% gradient (PAA 2/1, Pharmacia). Approximately 20 /xg of protein was applied to each well, and electrophoresis was carried out at 90 V for 12 hours at 4°C in a Tris/borate buffer (0.09 mol/L Tris, 0.08 mol/L boric acid, and 0.003 mol/L EDTA, pH 8.35). 30 A set of standard markers with known hydrated diameters (thyroglobulin, 170 A; ferritin, 122 A; catalase, 104 A; and lactate dehydrogenase, 81 A) was run on each slab as a reference. Gels were subsequently equilibrated in transfer buffer (see above).
Apolipoproteins. Apolipoprotein electrophoresis was performed in 5% to 19% gradient SDS poh/acrylamide gels according to the method of Laemmli. 31 Lipoprotein samples were solubilized and heated at 100°C for 5 minutes in 30 pL sample buffer containing SDS (1% SDS, 10 mmol/L Tris with or without 10 mmol/L dithiothreitol at pH 6.8). Twenty microliters of 50% sucrose/bromophenol blue was then added to each sample. Samples were loaded and gels electrophoresed at a current of 30 mA/slab at 15°C for 2 hours. Molecular-weight protein standards ranging from 29 to 205 kD (Sigma) were electrophoresed concomitantly.
Western Blots
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets 32 was used as the method for detection of TFPI in the protein moieties of the various subfractions. Immunoblotting was performed after electrophoresis of either native lipoproteins or apolipoproteins. Apolipoprotein or lipoprotein bands were electrophoretically blotted onto nitrocellulose sheets (Bio-Rad) for 1 hour and 12 hours, respectively. A transfer buffer containing 25 mmol/L Tris, 192 mmol/L glycine, and 20% methanol at pH 8.3 was used in a Transblot cell (Bio-Rad). Electrophoretic transfer was performed at 90 V. 32 The nitrocellulose paper was then blocked with 2.5% nonfat milk in TS buffer (0.05 mol/L Tris HC1, 0.15 mol/L NaCl, and 0.05% NaN 3 ) at by guest on http://atvb.ahajournals.org/ Downloaded from pH 7.5 for 1 hour at room temperature and incubated overnight at room temperature with rabbit anti-TFPI IgG's diluted 1:2500 in TBSA buffer (0.05 mol/L Tris HC1, 0.15 mol/L NaCl, 0.05% NaN 3 , and 0.17% BSA). The paper was then washed three times in TS containing 2.5% nonfat dry milk; the blots were subsequently incubated for 1 hour with a goat anti-rabbit IgG radiolabeled with 125 I (diluted 1:1000 in TBSA). After washing three times, blots were exposed to Kodak XAR film. Western blotting and immunodetection of Lp(a) were performed according to the protocol of Bronstein et al. 33 Antibody and antibody conjugate used for immunodetection were, respectively, an anti-human apo(a) (1:2000) prepared in sheep 28 and an anti-sheep IgGalkaline phosphatase (1:20 000) (Sigma).
Results
Characterization of Lipoprotein Subspecies
To evaluate the distribution of TFPI among the apo B-containing and apo A-I-containing lipoprotein subspecies, we fractionated the plasma lipoprotein spectrum by isopycnic density gradient ultracentrifugation. 25 We initially determined the density distribution, concentration, chemical composition, and apolipoprotein content of lipoprotein subspecies. The quantitative distribution of the various lipoprotein subspecies and of their triglyceride, phospholipid, cholesteryl ester, free cholesterol, and protein components are shown over the density range from 1.016 to 1.190 g/mL in the Table. This pattern was obtained from analyses of the 24 successive gradient fractions of 0.4 mL from plasma samples of eight subjects. The correspondence of density subtractions to lipoprotein subspecies was assessed on the basis of chemical, physical, and immunological analyses. 25 Note that VLDL and IDL (d< 1.019 g/mL) represent 4.6% of total lipoprotein mass, LDL (d= 1.019 to 1.063 g/mL) some 47.9%, and HDL (d=1.063 to 1.167 g/mL) some 39.7%. The profile of lipoprotein mass concentration as a function of density is shown in Fig 1A. The first fraction contained a mixture of VLDL of d< 1.006 g/mL and of IDL of d=1.006 to 1.018 g/mL (Table) . Fraction 2 corresponded to a subtraction of IDL (d= 1.018 to 1.019 g/mL). The following subtractions (No. 3 to 12) corresponded to LDL ranging in density from 1.019 to 1.063 g/mL. Fraction 13 (d= 1.063 to 1.072 g/mL) displayed a composition between those considered typical of LDL and HDL. On the basis of our earlier studies, 23 the hydrated densities of HDL 2 and HDL3 ranged, respectively, from 1.063 to 1.100 g/mL (subtractions 13 to 16) and from 1.100 to 1.167 g/mL (subtractions 17 to 22). Gradient fractions 23 and 24, of d=1.167 to 1.190 g/mL and containing -8 0 % of protein by weight, represent forms of VHDL, notably VHDL, (hydrated density -1.16 g/mL).
Distribution of TFPI Activity and TFPI Protein Among Lipoprotein Subspecies
All 24 lipoprotein subtractions were subsequently analyzed for TFPI activity (Fig IB) by the use of a chromogenic inhibition assay. While all lipoprotein subspecies displayed a basal level of TFPI activity (-20 arbitrary units of TFPI activity expressed as percent plasma per milligram of total lipoprotein mass), TFPI activity was specifically collocalized with apo B-containing lipoprotein subspecies ranging in density from 1.033 to 1.081 g/mL (subtractions 8 to 14; >40 arbitrary units of TFPI activity expressed as percent plasma per milligram of total lipoprotein mass) and with apo A-Icontaining subspecies ranging from d=1.133 to 1.190 g/mL (subtractions 20 to 24).
In the series of eight normolipidemic plasmas studied, the density distribution of the first peak of TFPI activity typically showed partial overlap with that of Lp(a) ( Figs  IB and 1C) . To verify whether TFPI activity and Lp(a) were codistributed, we quantified the Lp(a) content of all subtractions by ELISA (Fig 1C) . Such immunological detection revealed a major unique peak of Lp(a) near fraction 13 (d= 1.063 to 1.072 g/mL), thereby suggesting that TFPI was not codistributed with Lp(a). By contrast, TFPI appeared to be present mainly in denser LDL (subtractions 10 to 13) and in certain subtractions (12 to 15) containing both Lp(a) and HDL particles. The plasma profiles in two individual donors (Fig 2) revealed distinct density ranges for LDL and Lp(a) in these subjects. Thus, TFPI comigrated with dense LDL subtractions 9 to 11 (d=1.039 to 1.058 g/mL) in one individual (Fig 2A) ; in the second subject, however, the peaks of TFPI activity and Lp(a) occurred simultaneously in subtractions 10 to 13 (d=1.044 to 1.072 g/mL). Differences in circulating Lp(a) isoforms in these subjects (S3 in Fig 2A and F in Fig 2B, respectively) 34 may partially explain such distinct distributions. Furthermore, TFPI was present in the densest HDL fraction (20 to 24; d= 1.133 to 1.190 g/mL) in both subjects and may represent that bound to apo A-II by covalent linkage.
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To provide direct evidence for the association of TFPI protein with lipoprotein particles, qualitative immunodetection was performed on native lipoprotein subspecies in nondenaturing 2% to 16% gradient gels (Fig 3) as indicated above. The electrophoretic conditions did not appear to affect the potential relation between lipoprotein particles and TFPI, as TFPI was observed to comigrate with all lipoprotein species. Furthermore, the TFPI band associated with LDL particles whose hydrated diameters were in the range from 255 to 260 A had the strongest intensity by comparison with that associated with LDL subtractions of larger particle size (3 to 7; diameter of 260 to 280 A). The overlap in the density distribution of Lp(a) and HDL particles in subtractions 12 to 14 was resolved by nondenaturing and nonreducing gel electrophoresis. This methodology allowed discrimination between the preferential association of TFPI with Lp(a) or with light HDL 2 . Indeed, the band corresponding to the particle size of Lp(a) (-280 A) (Fig 3, fractions 11 to 15 ) had a higher reactivity after immunological detection than did the bands corresponding to the diameters of HDL 2 particles (subtractions 14 and 15). TFPI protein was also identified in HDL subtractions and more specifically in those of small particle size (subfractions 17 to 21; range in diameter of 82 to 112 A). The intensity of staining of HDL3 (subfractions 17 to 21; Fig 3) and VHDL (subtraction 23; Fig 3) was markedly greater than that of HDL 2 (subfractions 14 and 15; Fig 3) . The association of TFPI with Lp(a) particles was further analyzed by immunodetection of Lp(a) and TFPI under the same conditions as above (Fig 4) . In these studies, TFPI protein (Fig 4, lane 3) was located at the same position as that to which Lp(a) migrated (Fig 4, lane 2) , I-labeled anti-rabbit IgG, recognized a unique band that migrated with a relative molecular mass of 35 kD (Fig 2A) . The distribution of immunologically reactive TFPI among lipoprotein subspecies thus correlated well with TFPI activity (Fig 2A) .
Molecular-Weight Species of Lipoprotein-Associated TFPI
Several molecular-weight forms of TFPI were detected among lipoprotein subfractions, and these were visualized after SDS-PAGE on a 5% to 19% gel, followed by Western blotting, immunodetection, and autoradiography after treatment of the lipoprotein samples under denaturing and nonreducing conditions (Fig 5) . The results demonstrate that dense LDL subspecies of d=1.039 to 1.058 g/mL (8 to 12) transport mainly the 35-kD form of TFPI, whereas dense subspecies of HDL (subfractions 18 to 23 of d=1.110 to 1.167 g/mL) contain mainly the higher relative molecular mass form of 41 kD (a form that is known to be covalently associated with apo A-IP) and minor bands of the 35-kD and 52-kD forms.
Dissociation of Lipoprotein-Associated TFPI
We next asked whether the specific distribution of TFPI detected among LDL subspecies was not due to uncoupling of TFPI from LDL after contact with a salt solution (potassium bromide) of high ionic strength. LDLs were therefore isolated by gel filtration (see "Methods"). Subsequently, chromatographically isolated LDLs were treated separately with increasing concentrations of sodium chloride (0.15 to 2 mol/L). To separate any free TFPI dissociated from LDL, such LDLs were applied to a gel filtration column (see by 2 mol/L NaG. Identical experiments were performed with heparin (2 U/mL), a polyanion known to liberate TFPI from vascular endothelial cells, e-amino-n-caproic acid (5 mmol/L), and dithiothreitol (50 mmol/L) (data not shown). No additional TFPI was liberated from LDL by treatment with such agents.
Discussion The present studies demonstrate for the first time the heterogeneity of lipoprotein-mediated TFPI transport and more specifically the preferential association of TFPI activity and TFPI protein with subspecies of apo B -and apo A-I-containing particles. Furthermore, the our results indicate a slightly greater association of TFPI activity with HDL (54.4%) than with VLDL and LDL (45.6%). Indeed, the latter investigators 9 found 50% of TFPI to be associated with VLDL and LDL, 44% with HDL, and 6% with free TFPI. In the latter study, lipoproteins were separated by gel filtration and TFPI was quantified by immunoassay. Despite differences in the methodologies employed, these results are largely consistent, the minor discrepancy probably arising from use of different TFPI assays, which were functional in the present study and antigenic in that of Novotny et al. 9 The dense subspecies of HDL, (<i=1.133 to 1.167 g/mL) with which TFPI was preferentially associated were of small size, displayed a cholesteryl ester to protein ratio of -0.2, and were deficient in phospholipid (range, 13.6% to 18.3%). The presence of TFPI among HDL particles has been well documented. Indeed, several authors have suggested that TFPI may be associated with HDL as a result of its binding to apo A-II.
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- 35 This hypothesis was confirmed by Novotny et al, 9 who demonstrated that the 46-kD but not the 40-kD form of TFPI is in covalent linkage with apo A-II. Our findings also document the association of two distinct molecular-weight forms of TFPI (35 kD and 41 kD) with HDL particles. A note added in proof in the article of Novotny et al 9 indicated an error in the apparent molecular weights of standards used for SDS-PAGE by the manufacturer. Comparison of our data with the recalculated data of Novotny et al 9 gave similar values for the two major size species of TFPI. In addition, significant amounts of TFPI were associated with VHDL subfractions of d=1.167 to 1.190 g/mL.
The second major localization of TFPI was within the hydrated density range of dense LDL particles. Earlier studies of the distribution of TFPI among plasma lipoproteins did not discriminate between the presence of TFPI in triglyceride-rich compared with cholesterol-rich apo B-containing subspecies (VLDL and LDL, respectively). Our results demonstrate a major localization of TFPI with dense LDL (d= 1.033 to 1.063 g/mL) of small particle size, which in comparison with light LDL (d= 1.019 to 1.033 g/mL) exhibit a markedly lower proportion of triglyceride (5% versus 19%) and enrichment in cholesteryl ester (38% versus 30%). Analysis of the mean ratios of the percent mass of the various 17 Minor amounts of apo E (<0.5%) were, however, detected in the lightest and in densest LDL subspecies. 17 The presence of apo E at each extreme of the LDL spectrum does not correspond to the distribution of TFPI among LDL subspecies and therefore tends to exclude a specific association of TFPI with apo E. Furthermore, the apo E-rich fractions, ie, VLDL and IDL, did not appear to be efficient vectors of TFPI.
The third and new localization of TFPI was among Lp(a) particles. The protein moiety of Lp(a) is composed of one copy of apo B-100 disulfide-linked to apo(a), a highly glycated protein. Apo(a) is heterogeneous in size, exhibiting molecular mass isoforms ranging from -350 to 700 kD. 34 The variation in the number of repeat copies of the kringle-4-like domain accounts for the wide size range of apo(a). The various molecular-weight forms of apo(a) may provide an explanation for the distinct distribution of TFPI among Lp(a) isoforms (Fig 2) . High relative molecular mass isoforms display lower TFPI content than smaller forms. It is, therefore, tempting to speculate that the interaction of TFPI with Lp(a) is at least partially dependent on the size of apo(a), which for reasons of steric hindrance may prevent an efficient interaction between TFPI and the surface components of Lp(a) particles. Such a hypothesis may indirectly argue in favor of an interaction of TFPI with the "LDL" moiety of Lp(a). Furthermore, recent studies have demonstrated a proteolytic activity of human Lp(a) on synthetic peptide substrates, and especially on peptide substrate S2222. 37 Therefore, we asked whether Lp(a)-rich subfractions might interfere in the amidolytic assay of TFPI activity (data not shown). This assay was therefore performed in TSC buffer, but in the absence of coagulation factors, as described in the "Methods" section. Under these conditions no cleavage of S2222 was detected, thereby excluding the possible interference of apo(a) proteolytic activity in our evaluation of TFPI activity.
Although the association of TFPI with HDL appears to be covalent, the type of interaction involved in the association of TFPI with LDL and Lp(a) is indeterminate. We have ruled out a key role for ionic/polar interactions, since TFPI could not be dissociated by 2 mol/L NaCl or heparin (2 U/mL), which we expected would compete for possible binding with TFPI at the carbohydrate side chains of apo B or apo(a), respectively. Indeed, the common content of apo B-100 among LDL particles despite a discontinuous distribution of TFPI provokes the hypothesis that TFPI may interact with surface-exposed lipid components of LDL rather than with apo B. Nevertheless, alterations in apo B-100 conformation that parallel the modifications in the radius of curvature of LDL particles across the density distribution would equally explain the differential distribution of TFPI between dense, intermediate, and light LDL. The predicted amino acid sequence of TFPI contains no obvious hydrophobic region that might facilitate lipid binding. Certainly, the binding of TFPI to LDL does not appear to be exclusively electrostatic. We therefore conclude that among the spectrum of apo B-containing lipoprotein subspecies, small, dense LDL particles provide the most favorable surface structure for efficient TFPI binding.
Previous reports 18 -38 have established the existence of a positive correlation between plasma levels of dense LDL and atherosclerosis. On the other hand, expression of TF on the surface of lipid-laden macrophages 39 might play a role in fibrin deposition in atherosclerotic plaques; penetration of TFPI-bearing, dense LDL into the subendothelial space would potentially inhibit this process, in which case dense LDL would play an antiatherosclerotic role. Equally, however, the elevated susceptibility of dense LDL to oxidation, 
